The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

NCT06140576 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Sindilimab
DRUG: Nab-paclitaxel
DRUG: Lenvatinib

Sponsor

Zhejiang Cancer Hospital